| Q40142216 | Anticonvulsant drugs. An update |
| Q39502944 | Antiepileptic drug toxicity: definition and mechanism of action |
| Q40780187 | Antiepileptic drugs. A review of clinically significant drug interactions. |
| Q40866467 | Drug interactions in psychopharmacology. |
| Q39554942 | Drug interactions that matter. A critical reappraisal |
| Q40267248 | Drug interactions with valproic acid |
| Q34256087 | Drug treatment of epilepsy: a review |
| Q28365901 | In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9) |
| Q34346592 | Inhibition of phenobarbitone N-glucosidation by valproate |
| Q50124195 | Kinetics of phenobarbital in normal subjects and epileptic patients |
| Q34448568 | Methods of assessment of antiepileptic drugs |
| Q36305771 | Overtreatment in epilepsy: how it occurs and how it can be avoided |
| Q41271354 | Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations |
| Q40329711 | Pharmacokinetic interactions with antiepileptic drugs |
| Q37283169 | Prescription of psychoactive drugs in patients attended by the SUS at Manhuaçu - MG (Brazil). |
| Q71558781 | The effect of concurrent administration of valproate sodium on phenobarbital plasma concentration/dosage ratio in pediatric patients |
| Q43520387 | The effect of valproate on the metabolism of phenobarbital in the rat. |
| Q41602314 | Valproate-induced hepatic injury: analyses of 23 fatal cases |
| Q54510298 | Valproate-induced hepatic steatogenesis in rats. |